WEKO3
アイテム
Long-Term Survival and Risk of Second Cancers After Radiotherapy for Cervical Cancer
https://repo.qst.go.jp/records/44997
https://repo.qst.go.jp/records/449977468ffde-3936-46a1-84af-4a42f7bd71f7
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2007-10-16 | |||||
| タイトル | ||||||
| タイトル | Long-Term Survival and Risk of Second Cancers After Radiotherapy for Cervical Cancer | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Ohno, Tatsuya
× Ohno, Tatsuya× Kato, Shingo× Satou, Shinichirou× Fukuhisa, Kenjirou× Nakano, Takashi× Tsujii, Hirohiko× Arai, Tatsuo× 大野 達也× 加藤 眞吾× 佐藤 眞一郎× 福久 健二郎× 中野 隆史× 辻井 博彦× 荒居 龍雄 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Purpose To evaluate the feasibility of concurrent weekly Cis-platinum chemoradiation (CRT) in the curative treatment of primary vaginal cancer. \nMethods \nA retrospective review was performed of all primary vaginal cancer patients treated with curative intent at the Ottawa Hospital Regional Cancer Centre between 1999 and 2004 using concurrent Cis-platinum CRT. \nResults \nTwelve patients were treated with concurrent weekly CRT. The median age at diagnosis was 56 years (range, 34–69 years), and the median follow-up was 50 months (range, 11–75 months). Ten patients (83%) were diagnosed with squamous cell carcinoma and 2 patients (17%) with adenocarcinoma. The distribution according to stage was as follows: 6 (50%) Stage II, 4 (33%) Stage III, and 2 (17%) Stage IVA. All patients received pelvic external beam radiotherapy (EBRT) concurrently with weekly intravenous Cis-platinum chemotherapy (40 mg/m2) followed by brachytherapy (BT). The median dose of EBRT was 4500 cGy given in 25 fractions over 5 weeks. Ten patients received interstitial BT, and 2 patients received intracavitary BT, with the median dose being 3000 cGy. The 5-year overall survival, progression-free survival, and locoregional progression-free survival rates were 66%, 75%, and 92%, respectively. Late toxicity requiring surgery occurred in 2 patients (17%). \nConclusions \nFor the treatment of primary vaginal cancer, it is feasible to deliver concurrent weekly Cis-platinum chemotherapy with high-dose radiation, leading to excellent local control and an acceptable toxicity profile. |
|||||
| 書誌情報 |
International Journal of Radiation Oncology Biology Physics 巻 69, 号 3, p. 740-745, 発行日 2007-04 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0360-3016 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1016/j.ijrobp.2007.04.028 | |||||
